EN DE
Watch Spyre Therapeutics Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Spyre Therapeutics Inc. (SYRE) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Spyre Therapeutics Inc. stock $65.78, price $104, that is 37.0% below the price, quality 45 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

ST Spyre Therapeutics Inc. logo Thin data Nov 10, 2026

Spyre Therapeutics Inc.

SYRE · US
Very expensive, weak quality

Our calculation puts a fair price 37% below what the stock costs today.

Positive coverage
Quality 45/100
Mixed vs. peers (4/7)
Insiders sold $424.8M (6M)
Fair value $65.78 · Strongly overvalued
Weak Growth (revenue 3y −63.8 %/yr in USD)
Negative free cash flow
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Spyre Therapeutics Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$210.50 $2.65 Fair Value $65.78 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $2.65 – $210.50 · fair‑value band $49.33 – $82.22 · the $104.48 price screens above the $65.78 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Spyre Therapeutics in your weekly email

Every Wednesday you see whether Spyre Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.

Show moreShow less

The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023.

The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Stock analysis

Spyre Therapeutics Inc. (SYRE) currently trades at $104.48, while our estimate is $65.78, 37% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $49.33 (bear) to $82.22 (bull), the price of $104.48 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Spyre Therapeutics Inc. reported revenue of $0 in FY2025 versus $18.7M in FY2021. Reported net income was −$155M in FY2025.

Key figures

Market cap $9.9B Mid · EPS (TTM) $−2.68 · Return on equity −35.0% · Return on assets (EBIT) −62.2% (5-year average) · Free cash flow −$169M · Net cash $85.7M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 4% below its 52-week high and 371% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −37%, SYRE screens richer than that median.

Fair Value

Bear $49.33 Fair Value $65.78 Bull $82.22
Price $104.48 · Downside -37.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 45/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 70
Do the profits arrive as real cash?
Financial strength 84
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 79
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 97
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 7 officers or directors sold shares worth $424.8M and none bought.

  • SaleScott L BurrowsChief Financial Officer9× since Mar 3, 2026: 110,732 shares, avg. $82.40$9.1MOct 1, 2026
  • SaleCameron TurtleChief Executive Officer, Director11× since Dec 1, 2025: 165,000 shares, avg. $62.57$10.3MOct 1, 202610b5-1 plan
  • SaleHeidy King-JonesOfficer2× since Sep 1, 2026: 57,332 shares, avg. $89.21$5.1MOct 1, 202610b5-1 plan
  • SaleJeffrey W. AlbersDirector23,000 shares at $104.53$2.4MAug 7, 202610b5-1 plan
  • SaleSheldon SloanChief Medical Officer4× since Apr 1, 2026: 102,958 shares, avg. $71.43$7.4MJul 1, 202610b5-1 plan
  • SaleFairmount Funds Management LLCDirector4,684,781 shares at $85.31$399.7MJun 23, 2026
  • SaleMichael Thomas HendersonDirector2× since May 8, 2026: 100,000 shares, avg. $79.52$8.0MJun 22, 202610b5-1 plan

Plus 12 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+0.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−63.8%
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−19.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,169.3% (2018) → −23,540.2% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

SYRE screens overvalued: fair value 37% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (84 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Spyre Therapeutics Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 45 · Above median
Fair Value upside −37.0% · Below median
Profitability
Return on assets −20.0% · Above median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 13.87× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs SYRE
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs SYRE
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs SYRE
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs SYRE
argenx SE ARGX $971.55 $908.40 −7% vs SYRE
CSL Limited CSL A$201.68 A$181.40 −10% vs SYRE
Moderna, Inc MRNA $250.83 $158.70 −37% vs SYRE
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs SYRE
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs SYRE
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs SYRE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Spyre Therapeutics Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Spyre Therapeutics Inc. Fair Value". https://www.fairvalue-calculator.com/stock/SYRE

Frequently asked questions

Is Spyre Therapeutics Inc. (SYRE) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $65.78 versus a price of $104.48, about 37% lower (overvalued).
What is the fair value of SYRE?
Our estimate for Spyre Therapeutics Inc. is $65.78 (as of Nov 10, 2026), built from audited fundamentals. The current price: $104.48.
What is the quality score of SYRE?
Spyre Therapeutics Inc. has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Spyre Therapeutics Inc. (SYRE)?
Our calculated price target is the estimate of $65.78 (as of Nov 10, 2026). Cautious scenario $49.33, optimistic scenario $82.22. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Spyre Therapeutics Inc. stock forecast for 2026?
Our estimate puts fair value at $65.78, about 37% lower versus a price of $104.48 (overvalued). Cautious scenario $49.33, optimistic scenario $82.22. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Spyre Therapeutics Inc. (SYRE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Spyre Therapeutics Inc. it is $65.78 per share (as of Nov 10, 2026), against a price of $104.48.
Is Spyre Therapeutics Inc. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, SYRE trades above its calculated fair value: price $104.48, fair value $65.78, a gap of about −37% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SYRE?
No. The price is what the market pays today ($104.48); the fair value is what the company's own numbers justify ($65.78). For Spyre Therapeutics Inc. the two are $38.70 per share apart. That gap is exactly why we show both numbers side by side.
How much is Spyre Therapeutics Inc. worth?
The market values Spyre Therapeutics Inc. at about $9.9B (market capitalisation, as of Nov 10, 2026). Per share that is $104.48; our models calculate a fair value of $65.78 per share.
What do the bullish and bearish scenarios say about SYRE?
Our models span a range for Spyre Therapeutics Inc.: cautious scenario $49.33, base $65.78, optimistic $82.22 per share (as of Nov 10, 2026, price $104.48). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Spyre Therapeutics Inc. (SYRE)?
Balance-sheet figures for Spyre Therapeutics Inc. (as of Nov 10, 2026): return on equity −35.0%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is SYRE from its 52-week high?
Spyre Therapeutics Inc. trades at $104.48, about 4% below its 52-week high of $109.00 and 371% above the low of $22.18 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $65.78 is for.
Which stocks are comparable to Spyre Therapeutics Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Spyre Therapeutics Inc. stock attractive at the current price?
The data as of Nov 10, 2026: price $104.48, calculated fair value $65.78 (−37%), Quality Score 45/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Spyre Therapeutics Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Spyre Therapeutics Inc. (SYRE)?
The closing price on Nov 10, 2026 was $104.48. Our estimate is $65.78, about 37% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Spyre Therapeutics Inc. right now?
The price sits above even our optimistic bull case ($82.22). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Spyre Therapeutics Inc.

How large is the market capitalisation of Spyre Therapeutics Inc. (SYRE)?
The market capitalisation of Spyre Therapeutics Inc. is $9.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Spyre Therapeutics Inc. (SYRE)?
Earnings per share at Spyre Therapeutics Inc. are $−2.68. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Spyre Therapeutics Inc. (SYRE)?
The return on equity (ROE) of Spyre Therapeutics Inc. is −35.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Spyre Therapeutics Inc. (SYRE)?
On an EBIT basis the return on assets of Spyre Therapeutics Inc. is −62.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Spyre Therapeutics Inc. (SYRE) generate?
The free cash flow of Spyre Therapeutics Inc. is −$169M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Spyre Therapeutics Inc. (SYRE) hold?
Spyre Therapeutics Inc. holds more cash than debt, $85.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Spyre Therapeutics Inc. in the live analysis

One click puts Spyre Therapeutics Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.